Although there are currently no reports describing additional mechanisms on the inhibition of SMO-GLI in SCLC tumors, SMO antagonists, such as erismodegib and vismodegib, continue to be employed as they block cell proliferation and increase apoptosis. Here, GLI1 is linked to small cell lung carcinoma.